Phase 2 Peripheral Arterial Disease Trial, Recruiting (NCT06420752)

Phase 2 Peripheral Arterial Disease Trial, Recruiting NCT06420752 Sponsor: University of Wisconsin, La Crosse Condition: Peripheral Arterial Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06420752 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Arterial Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have a specific blood flow test result (called an ankle-brachial index) of 0.90 or lower, which can indicate reduced blood flow to the legs
Your condition has been stable for at least 3 months

Who may not be able to join:

You have been regularly exercising or taking part in a heart or circulation recovery programme in the past 3 months
You have severe problems with blood flow to your legs, have had an amputation, or experience leg pain even when resting
You have had major surgery or a procedure to improve blood flow in your legs within the last 3 months
You have heart failure
You have kidney disease
You are allergic to beetroot
You have Crohn's disease
You are currently a smoker

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jacob T Caldwell, Ph.D., Assistant Professor

Phone: 608-785-8684

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06420752

Sponsor: University of Wisconsin, La Crosse

Phase: Phase 2

Status: Recruiting

Condition: Peripheral Arterial Disease

Trial contact: 608-785-8684

More information: https://clinicaltrials.gov/study/NCT06420752

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have a specific blood flow test result (called an ankle-brachial index) of 0.90 or lower, which can indicate reduced blood flow to the legs
Your condition has been stable for at least 3 months

Who may not be able to join:

You have been regularly exercising or taking part in a heart or circulation recovery programme in the past 3 months
You have severe problems with blood flow to your legs, have had an amputation, or experience leg pain even when resting
You have had major surgery or a procedure to improve blood flow in your legs within the last 3 months
You have heart failure
You have kidney disease
You are allergic to beetroot
You have Crohn's disease
You are currently a smoker

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University of Wisconsin, La Crosse

Registry

ClinicalTrials.gov

Start date

20 May 2024

Est. completion

31 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Functional capacity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov